Explore the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults

This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with Dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC.

The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.

New York location for dermatology study by Equity Medical
Study Location
New York
Office Address

200 Amsterdam Ave. New York, NY 10023

Office Phone
646-413-6020

Overview

Recruiting start date
  • January 15, 2025
Duration
  • Up to 40 weeks
Population

18 Years and older (Adult, Older Adult)

Study Drug

Dupilumab

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply (at screening and baseline unless otherwise specified):

  • Participant must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent.

  • Participants with moderate-to-severe LSC, as defined by Investigator’s Global Assessment (IGA) score ≥3 and one or more of the following:

    • at least 1 single anogenital lesion;
    • at least 2 lesions including 1 lesion of ≥3 cm in diameter;
    • at least 1 severe lesion (IGA score = 4).
  • History of LSC for at least 6 months prior to the screening visit.
  • On the Worst-Itch Numerical Rating Scale (WI-NRS) ranging from 0 to 10, participants must have an average worst-itch of LSC score of ≥7 in the 7 days prior to Day 1. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. For participants who do not have at least 4 daily scores reported during the 7 days immediately preceding the planned randomization date, randomization can be postponed until this requirement is met, but without exceeding the 28-day maximum duration of the screening period.
  • History of failing a 2-week course of medium-to-superpotent topical corticosteroid (TCS) +/- topical calcineurin inhibitor (TCI) for the treatment of LSC within the last 6 months, unless TCS/TCI are medically not advisable. Patients with documented systemic treatment for LSC (other than antihistamines) in the past 6 months are also considered as inadequate responders to topical treatments and are potentially eligible for treatment with dupilumab after appropriate washout.
  • Appropriate contraceptive measures
Exclusion Criteria
  • Participants are excluded from the study if any of the following criteria apply (at screening and baseline unless otherwise specified):
  • Participants diagnosed with active lesions of prurigo nodularis (broadly distributed nodules) or active lesions of atopic dermatitis (AD) within 6 months, contact dermatitis, psoriasis, cutaneous T-cell lymphoma (CTCL) XE “CTCL” f Abbreviation t “cutaneous T-cell lymphoma” (or suspected of CTCL), vulvar lichen planus, or vulvar lichen sclerosus.
  • Presence of skin morbidities other than LSC that, in the opinion of the Investigator, may interfere with the assessment of the study outcomes. For example: scabies, insect bite, folliculitis, lymphomatoid papulosis, chronic actinic dermatitis, dermatitis herpetiformis, sporotrichosis, bullous disease, lichen planus hypertrophicus.
  • Severe concomitant illness(es) that, in the Investigator’s judgment, would adversely affect the participant’s participation in the study.
  • Severe psychiatric disease that, in the Investigator’s judgement, would affect the study intervention evaluation.
  • Having received or planning to use any of the treatments within the timeframe as specified in the protocol.
What You Can Expect

The study will include visits to our study center where the patient will initially receive a thorough physical examination, including an EKG and blood work at no cost to the patient to assess the participants baseline health. Moreover, the patient will receive a screening examination from a dermatology specialist to confirm the diagnosis of the study disease. After informed consent and if the participants elects to continue in the study, the patient will either be given the active medication (i.e. Dupilumab) or a placebo. There will be regular follow up visits to assess the effectiveness and safety of the therapies.

Studies
Contact us to join a dermatology study clinical trial

Contact Us Today!

Whether it be eczema, dandruff, or psoriasis, being a part of our research is an impactful way to explore treatments and medications. Even if there isn’t a current study that’s a perfect fit for you, take the first step and sign up to learn more and be considered for future studies in New York and Kentucky. Click the button below to get started!